-+ 0.00%
-+ 0.00%
-+ 0.00%

VistaGen Therapeutics Reports Phase 3 Fasedienol Trial Fails to Meet Primary Endpoint in Social Anxiety Disorder

Reuters·12/22/2025 22:29:41

Please log in to view news